|
1
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: A global and regional perspective. Oncologist. 15(Suppl
4): 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eggert T, McGlynn KA, Duffy A, Manns MP,
Greten TF and Altekruse SF: Fibrolamellar hepatocellular carcinoma
in the USA, 2000-2010: A detailed report on frequency, treatment
and outcome based on the Surveillance, Epidemiology, and End
Results database. United European Gastroenterol J. 1:351–357. 2013.
View Article : Google Scholar
|
|
3
|
Jaka H, Mshana SE, Rambau PF, Masalu N,
Chalya PL and Kalluvya SE: Hepatocellular carcinoma:
Clinicopathological profile and challenges of management in a
resource-limited setting. World J Surg Oncol. 12:2462014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Naugler WE, Alsina AE, Frenette CT,
Rossaro L and Sellers MT: Building the multidisciplinary team for
management of patients with hepatocellular carcinoma. Clin
Gastroenterol Hepatol. 13:827–835. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crissien AM and Frenette C: Current
management of hepatocellular carcinoma. Gastroenterol Hepatol (NY).
10:153–161. 2014.
|
|
6
|
Knudsen ES, Gopal P and Singal AG: The
changing landscape of hepatocellular carcinoma: Etiology, genetics,
and therapy. Am J Pathol. 184:574–583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kew MC: The role of cirrhosis in the
etiology of hepatocellular carcinoma. J Gastrointest Cancer.
45:12–21. 2014. View Article : Google Scholar
|
|
8
|
Tornai I: Role of environmental factors in
the etiology of hepatocellular carcinoma. Orv Hetil. 151:1132–1136.
2010.In Hungarian. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Senkerikova R, Frankova S, Sperl J,
Oliverius M, Kieslichova E, Filipova H, Kautznerova D, Honsova E,
Trunecka P and Spicak J: Incidental hepatocellular carcinoma: Risk
factors and long-term outcome after liver transplantation.
Transplant Proc. 46:1426–1429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamiyama T, Tahara M, Nakanishi K, Yokoo
H, Kamachi H, Kakisaka T, Tsuruga Y, Matsushita M and Todo S:
Long-term outcome of laparoscopic hepatectomy in patients with
hepatocellular carcinoma. Hepatogastroenterology. 61:405–409.
2014.PubMed/NCBI
|
|
11
|
Takaki S, Sakaguchi H, Anai H, Tanaka T,
Yamamoto K, Morimoto K, Nishiofuku H, Inoue M, Sueyoshi S, Nagata
T, et al: Long-term outcome of transcatheter subsegmental and
segmental arterial chemoemobolization using lipiodol for
hepatocellular carcinoma. Cardiovasc Intervent Radiol. 35:544–554.
2012. View Article : Google Scholar
|
|
12
|
Otsuji K, Takai K, Nishigaki Y, Shimizu S,
Hayashi H, Imai K, Suzuki Y, Hanai T, Ideta T, Miyazaki T, et al:
Efficacy and safety of cisplatin versus miriplatin in transcatheter
arterial chemoembolization and transarterial infusion chemotherapy
for hepatocellular carcinoma: A randomized controlled trial.
Hepatol Res. 45:514–522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishikawa T, Kubota T, Abe S, Watanabe Y,
Sugano T, Inoue R, Iwanaga A, Seki K, Honma T and Yoshida T:
Hepatic arterial infusion chemotherapy with cisplatin before
radical local treatment of early hepatocellular carcinoma (JIS
score 0/1) improves survival. Ann Oncol. 25:1379–1384. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Terazawa T, Kondo S, Hosoi H, Morizane C,
Shimizu S, Mitsunaga S, Ikeda M, Ueno H and Okusaka T:
Transarterial infusion chemotherapy with cisplatin plus S-1 for
hepatocellular carcinoma treatment: A phase I trial. BMC Cancer.
14:3012014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
An J, Wang X, Guo P, Zhong Y, Zhang X and
Yu Z: Hexabromocyclododecane and polychlorinated biphenyls increase
resistance of hepatocellular carcinoma cells to cisplatin through
the phosphatidylinositol 3-kinase/protein kinase B pathway. Toxicol
Lett. 229:265–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang D, Guo Y, Zhu Z and Chen W: Silence
of p15 expression by RNAi enhances cisplatin resistance in
hepatocellular carcinoma cells. Bosn J Basic Med Sci. 12:4–9.
2012.PubMed/NCBI
|
|
17
|
Kim Y, Jang M, Lim S, Won H, Yoon KS, Park
JH, Kim HJ, Kim BH, Park WS, Ha J, et al: Role of cyclophilin B in
tumorigenesis and cisplatin resistance in hepatocellular carcinoma
in humans. Hepatology. 54:1661–1678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Butler WT: Structural and functional
domains of osteopontin. Ann N Y Acad Sci. 760:6–11. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dai J, Cao Z, Kang Y, Fan K, Ji G, Yang H,
Wang H, Gao J, Wang H and Guo Y: A functional motif QLYxxYP is
essential for osteopontin induced T lymphocyte activation and
migration. Biochem Biophys Res Commun. 380:715–720. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao Z, Dai J, Fan K, Wang H, Ji G, Li B,
Zhang D, Hou S, Qian W, Zhao J, et al: A novel functional motif of
osteopontin for human lymphocyte migration and survival. Mol
Immunol. 45:3683–3692. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar S, Sharma P, Kumar D, Chakraborty G,
Gorain M and Kundu GC: Functional characterization of stromal
osteopontin in melanoma progression and metastasis. PLoS One.
8:e691162013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu M, Liu Q, Yi K, Wu L and Tan X: Effects
of osteopontin on functional activity of late endothelial
progenitor cells. J Cell Biochem. 112:1730–1736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu Y, Hu Y, Zhang ZY, Ye L, Xu FH,
Schneider ME, Ma XL, Du YX, Zuo XB, Zhou FS, et al: Genetic
association of osteopontin (OPN) and its receptor CD44 genes with
susceptibility to Chinese gastric cancer patients. J Cancer Res
Clin Oncol. 140:2143–2156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J, Liu Q, Wan Y, Zhao Z, Yu H, Luo H
and Tang Z: Osteopontin promotes the progression of gastric cancer
through the NF-κB pathway regulated by the MAPK and PI3K. Int J
Oncol. 45:282–290. 2014.PubMed/NCBI
|
|
25
|
Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu
N, Lan F, Liu Y, Yan S, Dong X, et al: Prognostic values of
osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer
Epidemiol. 37:985–992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Guo M, Chen JH, Wang Z, Du XF,
Liu PX and Li WH: Osteopontin knockdown inhibits αv,β
integrin-induced cell migration and invasion and promotes apoptosis
of breast cancer cells by inducing autophagy and inactivating the
PI3K/Akt/mTOR pathway. Cell Physiol Biochem. 33:991–1002. 2014.
View Article : Google Scholar
|
|
27
|
Hsieh IS, Huang WH, Liou HC, Chuang WJ,
Yang RS and Fu WM: Upregulation of drug transporter expression by
osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thoms JW, Dal Pra A, Anborgh PH,
Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M,
Catton C, Pintilie M, et al: Plasma osteopontin as a biomarker of
prostate cancer aggression: Relationship to risk category and
treatment response. Br J Cancer. 107:840–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ,
Ling XL and Ma SC: The prognostic value of osteopontin expression
in non-small cell lung cancer: A meta-analysis. J Mol Histol.
45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu TT, Han ZG, Shan L, Tao J, Zhang T,
Yuan SF and Shen HL: Expression of osteopontin in non-small cell
lung cancer and correlative relation with microvascular density.
Asian Pac J Cancer Prev. 15:29–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
El-Din Bessa SS, Elwan NM, Suliman GA and
El-Shourbagy SH: Clinical significance of plasma osteopontin level
in Egyptian patients with hepatitis C virus-related hepatocellular
carcinoma. Arch Med Res. 41:541–547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shang S, Plymoth A, Ge S, Feng Z, Rosen
HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L:
Identification of osteopontin as a novel marker for early
hepatocellular carcinoma. Hepatology. 55:483–490. 2012. View Article : Google Scholar
|
|
33
|
Kim SH, Chung YH, Yang SH, Kim JA, Jang
MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM, et al: Prognostic value
of serum osteopontin in hepatocellular carcinoma patients treated
with transarterial chemoembolization. Korean J Hepatol. 15:320–330.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Phillips RJ, Helbig KJ, Van der Hoek KH,
Seth D and Beard MR: Osteopontin increases hepatocellular carcinoma
cell growth in a CD44 dependant manner. World J Gastroenterol.
18:3389–3399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee
WC, Chen MF and Tsai CN: Recurrence and poor prognosis following
resection of small hepatitis B-related hepatocellular carcinoma
lesions are associated with aberrant tumor expression profiles of
glypican 3 and osteopontin. Ann Surg Oncol. 19(Suppl 3): S455–S463.
2012. View Article : Google Scholar
|
|
36
|
Daniele B: Current issues in the
management of hepatocellular carcinoma. Ann Oncol. 24(Suppl 2):
ii52013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qin L: Osteopontin is a promoter for
hepatocellular carcinoma metastasis: A summary of 10 years of
studies. Front Med. 8:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang R, Pan X, Huang Z, Weber GF and
Zhang G: Osteopontin enhances the expression and activity of MMP-2
via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines.
PLoS One. 6:e238312011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin F, Li Y, Cao J, Fan S, Wen J, Zhu G,
Du H and Liang Y: Overexpression of osteopontin in hepatocellular
carcinoma and its relationships with metastasis, invasion of tumor
cells. Mol Biol Rep. 38:5205–5210. 2011. View Article : Google Scholar
|
|
40
|
Chen RX, Xia YH, Xue TC, Zhang H and Ye
SL: Down-regulation of osteopontin inhibits metastasis of
hepatocellular carcinoma cells via a mechanism involving MMP-2 and
uPA. Oncol Rep. 25:803–808. 2011.
|
|
41
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang XJ, Feng CW and Li M: ADAM17 mediates
hypoxia-induced drug resistance in hepatocellular carcinoma cells
through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem.
380:57–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ,
Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, et al: Activation of
PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop
is involved in rapamycin resistance in hepatocellular carcinoma.
PLoS One. 7:e333792012. View Article : Google Scholar
|
|
44
|
Gu T, Ohashi R, Cui R, Tajima K, Yoshioka
M, Iwakami S, Sasaki S, Shinohara A, Matsukawa T, Kobayashi J, et
al: Osteopontin is involved in the development of acquired
chemo-resistance of cisplatin in small cell lung cancer. Lung
Cancer. 66:176–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
